Mounjaro explained: the honest picture on tirzepatide

The biggest misconception: Mounjaro is just another GLP-1 injection

The phrase "GLP-1 jab" has become shorthand for the whole category, which creates a real confusion about tirzepatide. Mounjaro is not a GLP-1 receptor agonist alone. It targets a second pathway (the glucose-dependent insulinotropic polypeptide receptor, or GIP) at the same time. Both GIP and GLP-1 are hormones released naturally after eating; they tell the brain you've had enough, and they slow down how fast the stomach empties. Activating both together appears to produce a stronger appetite-suppressing signal than either pathway alone. That distinction matters because it is the mechanism behind why results in clinical trials sit above those seen with earlier single-pathway medicines. The NHS patient information for tirzepatide sets this out clearly, and it is worth reading before you start any treatment. None of that means Mounjaro is suitable for everyone, or that the mechanism translates into identical outcomes for each person, biology varies, and the prescriber's job is to assess your specific picture. What it does mean is that comparing Mounjaro to older injections purely on the basis that they are all "weight-loss jabs" misses a clinically significant difference.

What the trial evidence actually shows, and how to read it honestly

SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes. At the 15 mg dose, participants lost around 20–21% of body weight on average over 72 weeks, alongside a reduced-calorie diet and increased activity. That is a meaningful figure. It is also a trial figure, participants were followed closely, doses were escalated on a fixed schedule, and the result reflects an average, not a guarantee for any individual. A small number of people lose more; some lose less. If you find yourself on Mounjaro and your progress feels slower than the headlines suggest, that is worth a conversation with your prescriber rather than a reason to abandon treatment. Our page on weight changes during treatment covers the practical side of what to do if the scales aren't moving as expected, and if you want a deeper look at the reasons behind unexpected gains, our guide to why weight gain can happen on Mounjaro explores the common causes in detail. Separately, the NICE technology appraisal TA1026, published in December 2024, reviewed this evidence and recommended tirzepatide for NHS use in eligible adults, a further mark of the trial programme's credibility.

The dosing schedule: adjustment before effect

A question our prescribers hear regularly is why the first pen feels underwhelming. The 2.5 mg starting dose exists to let your body adjust, it is a tolerability step, introduced because gastrointestinal side effects (nausea, loose stools, indigestion) are most likely in the early weeks and are significantly reduced by a gradual start. The dose is not doing much therapeutically at that level; the real effect builds as the prescriber steps you through 5, 7.5, 10, 12.5, and eventually 15 mg, usually at four-week intervals. Side effects tend to ease with time for most people, though they don't disappear for everyone, and if you want to read candid accounts from people working through the adjustment period, our Mounjaro forum covering difficult experiences brings together real patient perspectives. Each pen contains four doses and is kept refrigerated, a practical tip is to keep it somewhere you'll actually remember, like a shelf in the fridge door, so the routine sticks. Storage details and the precise room-temperature window for travel are covered in the Patient Information Leaflet; for anything about your own titration schedule, your prescriber is the right person to ask. If you're curious about what happens to a pen once it's been opened, our guide to Mounjaro once opened covers the practical storage questions.

Eligibility, prescribing, and what happens at the consultation

Mounjaro is licensed for adults, not under-18s. The starting point is a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not decide suitability; a prescriber looks at your full health picture, current medicines, and medical history. Certain conditions (including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require careful consideration and may affect whether treatment is appropriate. The medicine is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. People using oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced, and anyone using the contraceptive implant should read our page on tirzepatide and Nexplanon for specific guidance on how tirzepatide may interact with that method. If you want to understand how the private and NHS routes compare in terms of access and cost, our Mounjaro price comparison page sets out the landscape honestly. For a broader look at all available weight-loss treatment options, our treatment overview is a good place to start. And if you're ready to find out whether Mounjaro is clinically suitable for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not software.